3-Cyclohexyl-1-methyl-2-oxazol-5-yl-1H-indole-6-Carboxylic Acid | 494799-40-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-Cyclohexyl-1-methyl-2-oxazol-5-yl-1H-indole-6-Carboxylic Acid
• 英文别名: 3-Cyclohexyl-1-methyl-2-(1,3-oxazol-5-yl)indole-6-carboxylic acid
• CAS: 494799-40-5
• 化学式: C₁₉H₂₀N₂O₃
• 分子量: 324.379
• InChiKey: HGUSZLXUBIHCRB-UHFFFAOYSA-N

物化性质

• 沸点：
  567.6±50.0 °C(Predicted)
• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  68.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-Cyclohexyl-1-methyl-2-oxazol-5-yl-1H-indole-6-Carboxylic Acid 、 Ethyl 3-[4-[(2-amino-2-methylpropanoyl)amino]phenyl]prop-2-enoate 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 二甲基亚砜 为溶剂， 生成
  参考文献：
  名称：

  From benzimidazole to indole-5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase. Part 1: Indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons

  摘要：

  Replacement of the benzimidazole core of allosteric Thumb Pocket 1 HCV NS5B finger loop inhibitors by more lipophilic indole derivatives provided up to 30-fold potency improvements in cell-based subgenomic replicon assays. Optimization of C-2 substitution on the indole core led to the identification of analogs with EC50 <100 nM and modulated the pharmacokinetic properties of the inhibitors based on preliminary data from in vitro ADME profiles and in vivo rat PK. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.059

文献信息

• Viral polymerase inhibitors
  申请人：Boehringer Ingelheim (Canada) Ltd.

  公开号：US20030176433A1

  公开（公告）日：2003-09-18

  An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula I: 1 wherein: A is O, S, NR 1 , or CR 1 , wherein R 1 is defined herein; ---- represents either a single or a double bond; R 2 is selected from: H, halogen, R 21 , OR 21 , SR 21 , COOR 21 , SO 2 N(R 22 ) 2 , N(R 22 ) 2 , CON(R 22 ) 2 , NR 22 C(O)R 22 or NR 22 C(O)NR 22 wherein R 21 and each R 22 is defined herein; B is NR 3 or CR 3 , with the proviso that one of A or B is either CR 1 or CR 3 , wherein R 3 is defined herein; K is N or CR 4 , wherein R 4 is defined herein; L is N or CR 5 , wherein R 5 has the same definition as R 4 defined above; M is N or CR 7 , wherein R 7 has the same definition as R 4 defined above; Y 1 is O or S; Z is N(R 6a )R 6 or OR 6 , wherein R 6a is H or alkyl or NR 61 R 62 wherein R 61 and R 62 are defined herein; a salt or a derivative thereof, as an inhibitor of HCV NS5B polymerase.

  化合物的异构体，对映异构体，顺反异构体或互变异构体，由以下式I表示： 1 其中： A为O，S，NR 1 或CR 1 ，其中R 1 在此处定义； ----表示单键或双键之一； R 2 从以下选取：H，卤素，R 21 ，OR 21 ，SR 21 ，COOR 21 ，SO 2 N(R 22 ) 2 ，N(R 22 ) 2 ，CON(R 22 ) 2 ，NR 22 C(O)R 22 或NR 22 C(O)NR 22 其中R 21 和每个R 22 在此处定义； B为NR 3 或CR 3 ，但A或B中的一个为CR 1 或CR 3 ， 其中R 3 在此处定义； K为N或CR 4 ，其中R 4 在此处定义； L为N或CR 5 ，其中R 5 的定义与上述定义的R 4 相同； M为N或CR 7 ，其中R 7 的定义与上述定义的R 4 相同； Y 1 为O或S； Z为N(R 6a )R 6 或OR 6 ，其中R 6a 为H或烷基或NR 61 R 62 其中R 61 和R 62 在此处定义； 作为HCV NS5B聚合酶的抑制剂的盐或其衍生物。
• 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor
  申请人：Mizojiri Ryo

  公开号：US20090036444A1

  公开（公告）日：2009-02-05

  The present invention relates to a fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由以下式[I]表示的融合环化合物，其中每个符号如规范中所定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物基于HCV聚合酶抑制活性具有抗HCV活性，是一种预防或治疗丙型肝炎的药剂。
• Viral Polymerase Inhibitors
  申请人：Beaulieu Louis Pierre

  公开号：US20060293306A1

  公开（公告）日：2006-12-28

  An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula I: wherein: A is O, S, NR 1 , or CR 1 , wherein R 1 is defined herein; — represents either a single or a double bond; R 2 is selected from: H, halogen, R 21 , OR 21 , SR 21 , COOR 21 , SO 2 N(R 22 ) 2 , N(R 22 ) 2 , CON(R 22 ) 2 , NR 22 C(O)R 22 or NR 22 C(O)NR 22 wherein R 21 and each R 22 is defined herein; B is NR 3 or CR 3 , with the proviso that one of A or B is either CR 1 or CR 3 , wherein R 3 is defined herein; K is N or CR 4 , wherein R 4 is defined herein; L is N or CR 5 wherein R 5 has the same definition as R 4 defined above; M is N or CR 7 , wherein R 7 has the same definition as R 4 defined above; Y 1 is O or S; Z is N(R 6a )R 6 or OR 6 , wherein R 6a is H or alkyl or NR 61 R 62 wherein R 61 and R 62 are defined herein; a salt or a derivative thereof, as an inhibitor of HCV NS5B polymerase.

  化合物的异构体、对映异构体、顺反异构体或互变异构体，由式I表示：其中：A为O、S、NR1或CR1，其中R1如本文所定义；—代表单键或双键；R2选自：H、卤素、R21、OR21、SR21、COOR21、SO2N(R22)2、N(R22)2、CON(R22)2、NR22C(O)R22或NR22C(O)NR22，其中R21和每个R22如本文所定义；B为NR3或CR3，但其中一个为CR1或CR3，其中R3如本文所定义；K为N或CR4，其中R4如本文所定义；L为N或CR5，其中R5与上述R4定义相同；M为N或CR7，其中R7与上述R4定义相同；Y1为O或S；Z为N(R6a)R6或OR6，其中R6a为H或烷基，或NR61R62，其中R61和R62如本文所定义；其盐或衍生物，作为HCV NS5B聚合酶的抑制剂。
• Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
  申请人：Oka Takahiro

  公开号：US20070049593A1

  公开（公告）日：2007-03-01

  The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种四环融合杂环化合物，其化学式为[I]，其中每个符号的定义如规范中所述，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物表现出基于HCV聚合酶抑制活性的抗HCV活性，因此可用作预防或治疗丙型肝炎的药物。
• TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR
  申请人：Oka Takahiro

  公开号：US20120070409A1

  公开（公告）日：2012-03-22

  The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种四环融合杂环化合物，其表示为以下公式[I]，其中每个符号如规范中所定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物基于HCV聚合酶抑制活性显示出抗HCV活性，可用作预防或治疗丙型肝炎的药物。